Holen Sie sich die Stockscreener-App
9.80
0.72%
0.07
Handel nachbörslich:
9.80
Schlusskurs vom Vortag:
$9.73
Offen:
$9.68
24-Stunden-Volumen:
3.36M
Relative Volume:
1.31
Marktkapitalisierung:
$2.93B
Einnahmen:
$493.67M
Nettoeinkommen (Verlust:
$-104.69M
KGV:
-15.31
EPS:
-0.64
Netto-Cashflow:
$-31.51M
1W Leistung:
+4.70%
1M Leistung:
+2.19%
6M Leistung:
+0.00%
1J Leistung:
-23.68%
1-Tages-Spanne:
$9.60
$9.88
1-Wochen-Bereich:
$9.275
$9.99
52-Wochen-Spanne:
$9.02
$14.57
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Firmenname
Amicus Therapeutics Inc
Sektor
Branche
Telefon
(609) 662-2000
Adresse
47 HULFISH STREET, PRINCETON, NJ
Vergleichen Sie FOLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
9.80 | 2.93B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Eingeleitet | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2024-05-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Fortgesetzt | Goldman | Neutral |
| 2022-01-14 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-27 | Eingeleitet | Needham | Hold |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2021-02-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-02-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-06-05 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Eingeleitet | Janney | Buy |
| 2019-01-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Eingeleitet | Citigroup | Neutral |
| 2018-08-17 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
| 2017-09-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-08-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-01-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Eingeleitet | BofA/Merrill | Buy |
| 2016-04-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2016-04-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2015-09-16 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Fabry Disease Treatment Market Growth in Future Scope 2024-2031 - openPR
FOLD: 3 High-Growth Biotech Stocks to Watch - StockNews.com
Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to "Hold" at StockNews.com - MarketBeat
Y Intercept Hong Kong Ltd Has $374,000 Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Up 5.2%Time to Buy? - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lessened by Orion Portfolio Solutions LLC - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down – Here’s What Happened - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap DownTime to Sell? - MarketBeat
Morgan Stanley upgrades PTC, cuts Immuneering, Amicus (PTCT:NASDAQ) - Seeking Alpha
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? - Yahoo Finance
Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy? - MSN
Morgan Stanley cuts Amicus Therapeutics shares to Equalweight rating By Investing.com - Investing.com UK
Amicus Therapeutics' (FOLD) Equal Weight Rating Reaffirmed at Morgan Stanley - MarketBeat
Neo Ivy Capital Management Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 47,310 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Fmr LLC Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Old West Investment Management LLC Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Upgraded to Buy at StockNews.com - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stake Raised by Wellington Management Group LLP - MarketBeat
Point72 Asset Management L.P. Makes New $13.53 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Point72 DIFC Ltd Invests $704,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Janus Henderson Group PLC Trims Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Holdings Cut by Redmile Group LLC - MarketBeat
Parkman Healthcare Partners LLC Has $6.47 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Erste Asset Management GmbH Makes New $1.25 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
BNP Paribas Financial Markets Purchases 225,222 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics CEO Campbell Bradley sells $75,124 in stock - Investing.com India
Amicus Therapeutics CEO Campbell Bradley sells $75,124 in stock By Investing.com - Investing.com UK
Pompe Disease Market is expected to rise at a Significant CAGR, DelveInsight | Pompe Disease Therapies, Clinical trials, Treatment Options, Companies | Genzyme, Sanofi, Amicus Therapeutics, Actus - The Globe and Mail
Pompe Disease Market is expected to rise at a Significant CAGR, - openPR
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Boosted by Edgestream Partners L.P. - MarketBeat
PDT Partners LLC Buys New Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Intech Investment Management LLC Takes $834,000 Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Algert Global LLC Purchases 170,575 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Massachusetts Financial Services Co. MA Has $33.75 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Increases Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Principal Financial Group Inc. Lowers Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
(FOLD) Technical Data - Stock Traders Daily
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Victory Capital Management Inc. - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at StockNews.com - MarketBeat
Redmile Group, LLC Increases Stake in Amicus Therapeutics Inc - GuruFocus.com
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Acquires Shares in Amic - GuruFocus.com
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated - MSN
Avoro Capital Advisors LLC Adjusts Stake in Amicus Therapeutics Inc - GuruFocus.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by GSA Capital Partners LLP - MarketBeat
Finanzdaten der Amicus Therapeutics Inc-Aktie (FOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):